The Rutgers Institute for Translational Medicine and Science is planning a phase 2 trial of Evelo Bioscience’s investigational anti-inflammatory treatment for COVID-19 patients.

The study will evaluate if EDP1815 can prevent progression of COVID-19 symptoms and the development of COVID-related complications like cytokine storm. The trial will initially involve 60 patients admitted to the emergency room within 36 hours of testing positive for the virus.

Early clinical data suggest that the anti-inflammatory could control immune pathways associated with cytokine storm and resolve inflammation without causing complete immunosuppression.